ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2023
Racial Disparities in Diabetes Technology Adoption and Their Association with HbA1c and Diabetic Ketoacidosis.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Psychometric Properties of the Automated Insulin Delivery: Benefits and Burdens Scale for Adults with Type 1 Diabetes.Diabetes technology & therapeutics · 2024Trial
- US race/ethnic disparities in diabetes technologies: a systematic review and meta-analysis of 950 000 individuals.Journal of the Endocrine Society · 2026Review
- Navigating Continuous Glucose Monitoring Adoption: Insights From Hispanic Adults With Insulin-Treated Type 2 Diabetes.Journal of diabetes research · 2026Article
- Disparities in access to and use of diabetes technologies and therapeutics: a narrative review.Diabetologia · 2025Review
- Practical Considerations and Implementation of Automated Insulin Delivery Systems.Journal of diabetes science and technology · 2025Review
- Practical Considerations and Implementation of Automated Insulin Delivery Systems.Diabetes technology & therapeutics · 2025Review
- SCI - U: Validation of an updated Self-Care Inventory for contemporary diabetes management in adolescents with type 1 diabetes.Diabetes research and clinical practice · 2025Article
- Racial Disparities in the Use of Automated Insulin Delivery Systems in Youth With Type 1 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Effectiveness of Continuous Glucose Monitoring in a Pharmacist-Run Collaborative Drug Therapy Management Service for Underserved Individuals With Diabetes: A Quasi-Experimental Study.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Race and ethnic disparities in insulin pump and continuous glucose monitor use between 2017 and 2024: a systematic review with a focus on health equity.Journal of health equity · 2025Article
- Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective.Journal of the Endocrine Society · 2024Review
- Advances in diabetes technology within the digital diabetes ecosystem.Journal of managed care & specialty pharmacy · 2024Review
- Social and Structural Determinants of Cardiovascular Complications of Diabetes.Current diabetes reports · 2024Review
- Technology usage and glycaemic outcomes in a single tertiary centre with an ethnically diverse and socioeconomically deprived cohort of children with type 1 diabetes mellitus.Frontiers in clinical diabetes and healthcare · 2024Article
- Evaluating a systematic intensive therapy using continuous glucose monitoring and intermittent scanning glucose monitoring in clinical diabetes care: a protocol for a multi-center randomized clinical trial.Frontiers in clinical diabetes and healthcare · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Aim: Poorer glycemic control and higher diabetic ketoacidosis (DKA) rates are seen in racial/ethnic minorities with type 1 diabetes (T1D). Use of diabetes technologies such as continuous glucose monitors (CGM), continuous subcutaneous insulin infusion (CSII) and automated insulin delivery (AID) systems has been shown to improve glycemic control and reduce DKA risk. We examined race/ethnicity differences in diabetes technology use and their relationship with HbA1c and DKA. Methods: Data from patients aged ≥12 years with T1D for ≥1 year, receiving care from a single diabetes center, were examined. Patients were classified as Non-Hispanic White (n=3945), Non-Hispanic Black (Black, n=161), Hispanic (n=719), and Multiracial/Other (n=714). General linear models and logistic regression were used. Results: Black (OR=0.22, 0.15-0.32) and Hispanic (OR=0.37, 0.30-0.45) patients were less likely to use diabetes technology. This disparity was greater in the pediatric population (p-interaction=0.06). Technology use associated with lower HbA1c in each race/ethnic group. Among technology users, AID use associated with lower HbA1c compared to CGM and/or CSII (HbA1c of 8.4% vs 9.2%, respectively), with the greatest difference observed for Black adult AID users. CSII use associated with a lower odds of DKA in the past year (OR=0.73, 0.54-0.99), a relationship that did not vary by race (p-interaction =0.69); this inverse association with DKA was not observed for CGM or AID. Conclusion: Disparities in diabetes technology use, DKA, and glycemic control were apparent among Black and Hispanic patients with T1D. Differences in technology use ameliorated but did not fully account for disparities in HbA1c or DKA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.